Known targets — ChEMBL curated mechanism
POLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PRIM1PRIM2
The experimentally established mechanism targets of Cytarabine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 3/20 | 1.00 |
| ▸ | MTOR | P42345 | 2/20 | 1.00 |
| ▸ | THRB | P10828 | 1/20 | 1.00 |
| ▸ | MDM2 | Q00987 | 1/20 | 1.00 |
| ▸ | NCOA1 | Q15788 | 1/20 | 1.00 |
| ▸ | NCOA3 | Q9Y6Q9 | 1/20 | 1.00 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.64 |
| ▸ | GMNN | O75496 | 1/20 | 0.64 |
| ▸ | TP53 | P04637 | 1/20 | 0.64 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.64 |
| ▸ | DNMT1 | P26358 | 1/20 | 0.64 |
| ▸ | THPO | P40225 | 1/20 | 0.64 |
| ▸ | HTT | P42858 | 1/20 | 0.64 |
| ▸ | RAB9A | P51151 | 1/20 | 0.64 |
| ▸ | BLM | P54132 | 1/20 | 0.64 |
| ▸ | HBB | P68871 | 1/20 | 0.64 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.64 |
| ▸ | MAPT | P10636 | 1/20 | 0.61 |
| ▸ | CDA | P32320 | 1/20 | 0.61 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.61 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Cytarabine SCHEMBL787927 | 1.00 | LMNA (1.00) | LMNAMTORTHRBMDM2NCOA1 | |
| Cytarabine SCHEMBL471171 | 1.00 | LMNA (1.00) | LMNAMTORTHRBMDM2NCOA1 | |
| Cytarabine SCHEMBL12202579 | 1.00 | LMNA (1.00) | LMNAMTORTHRBMDM2NCOA1 | |
| Cytarabine SCHEMBL329878 | 1.00 | LMNA (1.00) | LMNAMTORTHRBMDM2NCOA1 | |
| Cytarabine SCHEMBL172274 | 1.00 | LMNA (1.00) | LMNAMTORTHRBMDM2NCOA1 | |
| Cytarabine SCHEMBL14644972 | 1.00 | LMNA (1.00) | LMNAMTORTHRBMDM2NCOA1 | |
| Cytarabine SCHEMBL23066241 | 1.00 | LMNA (1.00) | LMNAMTORTHRBMDM2NCOA1 | |
| Cytarabine SCHEMBL17993618 | 1.00 | LMNA (1.00) | LMNAMTORTHRBMDM2NCOA1 | |
| Cytarabine SCHEMBL14853684 | 1.00 | LMNA (1.00) | LMNAMTORTHRBMDM2NCOA1 | |
| Cytarabine SCHEMBL20546595 | 1.00 | LMNA (1.00) | LMNAMTORTHRBMDM2NCOA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 220816 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260144879-A1 | ANTI-VIRAL AND HEPATIC-TARGETED DRUGS | AI-BIOPHARMA (FR) | 2026-05-28 | — | — | US | claimed |
| EP-4746876-A1 | UDP-GLUCOSE CERAMIDE GLUCOSYLTRANSFERASE SYNTHASE (UGCG) INHIBITORS IN THE TREATMENT OF CANCER | Katholieke Universiteit Leuven (BE) | 2026-05-27 | — | — | EP | claimed |
| EP-3607938-B1 | PHARMACEUTICAL COMPOSITION | SOVIC BRKICIC LJILJANA (HR) | 2026-05-27 | — | — | EP | claimed |
| EP-4747263-A1 | LIPID NANOPARTICLES AND USES THEREOF | University of Connecticut (US) | 2026-05-27 | — | — | EP | claimed |
| EP-4748859-A2 | CHEMICALLY AND PHOTOCHEMICALLY INITIATED CELL MEMBRANE BLEBBING TO INDUCE CELL VESICLE PRODUCTION, MODIFICATIONS THEREOF, AND USES THEREOF | The Regents of the University of California (US) | 2026-05-27 | — | — | EP | claimed |
| CN-116209439-B | Cereblon protein modulators | Saint Jude Children's Research Hospital Ltd. (US) | 2026-05-26 | — | — | CN | claimed |
| US-20260137686-A1 | SOLID PHARMACEUTICAL FORMULATION OF PARP INHIBITORS AND USE THEREOF | IMPACT THERAPEUTICS SHANGHAI INC (CN) | 2026-05-21 | — | — | US | claimed |
| US-20260137700-A1 | PHARMACEUTICAL COMBINATION OF PRMT5 INHIBITOR AND DNA DAMAGE-INDUCING SUBSTANCE | SK BIOPHARMACEUTICALS CO LTD (KR) | 2026-05-21 | — | — | US | claimed |
| US-20260137674-A1 | COMBINATION THERAPY USING A KRAS G12D INHIBITOR, AND A NUCLEOSIDE ANALOG, AND/OR A MICROTUBULE INHIBITOR | INCYTE CORP (US) | 2026-05-21 | — | — | US | claimed |
| WO-2026105121-A1 | ANTICANCER FORMULATIONS AND USES THEREOF | INTRAGEL THERAPEUTICS LTD. (IL) | 2026-05-21 | — | — | WO | claimed |
| US-4283394-A | ANTICARCINOGENIC AGENTS | RESEARCH CORPORATION (US) | 1981-08-11 | — | — | US | claimed |
| WO-1981002164-A1 | SEVEN-MEMBERED RING COMPOUNDS AS INHIBITORS OF CYTIDINE DEAMINASE | US COMMERCE (US) | 1981-08-06 | — | — | WO | claimed |
| US-4275057-A | CANCER AND ANTITUMOR DRUG RESEARCH | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE DEPARTMENT OF HEALTH, EDUCATION AND WELFARE (US) | 1981-06-23 | — | — | US | claimed |
| WO-1981001145-A1 | HYDROLYTIC ENZYME-ACTIVATIBLE PRO-DRUGS | UNIV ILLINOIS (US) | 1981-04-30 | — | — | WO | claimed |
| WO-1981000410-A1 | CYTOTOXIC NUCLEOSIDE-CORTICOSTEROID PHOSPHODIESTERS | RESEARCH CORP (US) | 1981-02-19 | — | — | WO | claimed |
| EP-0010964-A1 | Ravidomycin, process of preparation and pharmaceutical compositions containing same | AYERST, MCKENNA AND HARRISON INC. (CA) | 1980-05-14 | — | — | EP | claimed |
| US-4145414-A | ANTIVIRAL, IMMUNOSUPPRESSIVE, ANTILEUKEMIA | THE UPJOHN COMPANY (US) | 1979-03-20 | — | — | US | claimed |
| US-4093607-A | ANTITUMOR ANTIBODY, ANTICANCER DRUG | YEDA RESEARCH AND DEVELOPMENT CO., LTD. (IL) | 1978-06-06 | — | — | US | claimed |
| US-4017606-A | CYTOSINE ARABINOSIDE AND HYDROGENATED PYRIMIDINE NUCLEOSIDES | THE UPJOHN COMPANY (US) | 1977-04-12 | — | — | US | claimed |
| US-3950325-A | Novel process for preparing 2,2'-cyclocytidine or 1-β-D-arabinofuranosyl cytosine | TANABE SEIYAKU CO., LTD. (JA) | 1976-04-13 | — | — | US | claimed |